We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Veeva Systems (VEEV) Makes Change to Front Office (revised)
Read MoreHide Full Article
Veeva Systems’ (VEEV - Free Report) shares lost 6.1% on Apr 2, following the mutually agreed-to announcement of the company’s CFO Brent Bowman's departure.
Bowman's departure, though unexpected, is not linked to any misconduct or financial disagreements. He will continue to work as an employee of VEEV for three months to aid in the transition. Tim Cabral, a former CFO of Veeva Systems, will step in as interim CFO until a permanent replacement is found. Additionally, the company announced other changes in its executive team, including the appointment of a new president, chief of staff and a chief marketing officer.
Despite this, the stock remains up 12.4% year to date, indicating investors’ confidence in the company's long-term prospects as it targets a growing industry that is up 17.1% in the same time period. The S&P 500 Index has gained 9.9% year to date.
Image Source: Zacks Investment Research
What Lies Ahead?
While the sudden change in leadership raised concerns among investors, analysts at Stifel believe that this move is unlikely to lead to major strategic or operational changes at Veeva. They noted that Bowman was performing well in his role, suggesting that his departure might be related to organizational restructuring rather than performance issues.
The market's reaction to Bowman's departure underscores the importance of strong financial leadership in maintaining investors’ confidence. While Veeva Systems’ share price dropped initially, the long-term impact will depend on the company's ability to smoothly transition to new leadership and continue its growth trajectory. Investors will possibly monitor VEEV's financial performance and any update regarding the search for a new CFO.
Currently, Veeva Systems carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space areDaVita Inc. (DVA - Free Report) , Cardinal Health, Inc. (CAH - Free Report) and Cencora, Inc. (COR - Free Report) .
DaVita, carrying a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 12.1%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 35.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita’s shares have risen 28.9% compared with the industry’s 9.6% growth in the past year.
Cardinal Health, carrying a Zacks Rank of 1 at present, has an estimated long-term growth rate of 14.2%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 15.6%.
CAH’s shares have risen 10.4% year to date compared with the industry’s 6.2% growth.
Cencora, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 9.8%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.7%.
Cencora’s shares have rallied 18.4% year to date compared with the industry’s 6.9% growth.
(NOTE: We are reissuing this article to clarify the nature of Brent Bowman's stepping down. The original version, posted earlier today, April 3, 2024, shall no longer be relied upon.)
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Veeva Systems (VEEV) Makes Change to Front Office (revised)
Veeva Systems’ (VEEV - Free Report) shares lost 6.1% on Apr 2, following the mutually agreed-to announcement of the company’s CFO Brent Bowman's departure.
Bowman's departure, though unexpected, is not linked to any misconduct or financial disagreements. He will continue to work as an employee of VEEV for three months to aid in the transition. Tim Cabral, a former CFO of Veeva Systems, will step in as interim CFO until a permanent replacement is found. Additionally, the company announced other changes in its executive team, including the appointment of a new president, chief of staff and a chief marketing officer.
Despite this, the stock remains up 12.4% year to date, indicating investors’ confidence in the company's long-term prospects as it targets a growing industry that is up 17.1% in the same time period. The S&P 500 Index has gained 9.9% year to date.
Image Source: Zacks Investment Research
What Lies Ahead?
While the sudden change in leadership raised concerns among investors, analysts at Stifel believe that this move is unlikely to lead to major strategic or operational changes at Veeva. They noted that Bowman was performing well in his role, suggesting that his departure might be related to organizational restructuring rather than performance issues.
The market's reaction to Bowman's departure underscores the importance of strong financial leadership in maintaining investors’ confidence. While Veeva Systems’ share price dropped initially, the long-term impact will depend on the company's ability to smoothly transition to new leadership and continue its growth trajectory. Investors will possibly monitor VEEV's financial performance and any update regarding the search for a new CFO.
Veeva Systems Inc. Price
Veeva Systems Inc. price | Veeva Systems Inc. Quote
Zacks Rank & Key Picks
Currently, Veeva Systems carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space areDaVita Inc. (DVA - Free Report) , Cardinal Health, Inc. (CAH - Free Report) and Cencora, Inc. (COR - Free Report) .
DaVita, carrying a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 12.1%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 35.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita’s shares have risen 28.9% compared with the industry’s 9.6% growth in the past year.
Cardinal Health, carrying a Zacks Rank of 1 at present, has an estimated long-term growth rate of 14.2%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 15.6%.
CAH’s shares have risen 10.4% year to date compared with the industry’s 6.2% growth.
Cencora, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 9.8%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.7%.
Cencora’s shares have rallied 18.4% year to date compared with the industry’s 6.9% growth.
(NOTE: We are reissuing this article to clarify the nature of Brent Bowman's stepping down. The original version, posted earlier today, April 3, 2024, shall no longer be relied upon.)